U.S. Markets closed

Exelixis, Inc. (EXEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.59+0.24 (+1.03%)
At close: 4:00PM EDT

23.55 -0.04 (-0.17%)
After hours: 6:16PM EDT

People also watch
ARRYINCYIMGNCLDXSGEN
  • A
    Albert88
    Albert88
    This stock is going to have a massive uptrend.
  • j
    jim
    jim
    my calculation on the envelop: there're 63990 new cases of RCC in US, say EXEL can take 20% of it, 12798, with $100000 price, that is 1.279 billion. Assume 70% margin, 20 PE, it comes as 17.9 billion market cap, We are now only 7-8 Billion market cap.
  • J
    Jan
    Jan
    3 Reasons to Buy the Dip With Exelixis ...
  • t
    tim
    tim

    Wow, the author thinks Cobi can be bigger than Cabo...
    2. Partnered programs
    While cabozantinib deservedly gets the most attention from investors, Exelixis' other approved drug, cobimetinib (marketed as Cotellic), could become a much bigger winner in the future. Exelixis CEO Michael Morrissey said at the Cantor Fitzgerald Global Healthcare Conference on Monday that his company was a "somewhat bystander" with the drug, since its partner Roche (NASDAQOTH:RHHBY) runs the show for cobimetinib for the most part. However, Exelixis is definitely an interested bystander.
    https://www.fool.com/investing/2017/09/26/3-reasons-to-buy-the-dip-with-exelixis.aspx?yptr=yahoo

    3 Reasons to Buy the Dip With Exelixis
    Does the recent drop of Exelixis stock mean doom and gloom for the biotech? Not at all.
    www.fool.com
  • p
    paul
    paul
    Motley Fools Sunday article is suggesting that EXEL is a MONSTER stock, whose market cap is likely to multiply!! 2 days after a negative article that probably contributed to the 12% drop on Friday!! If this Is not market manipulation, then this financial schizophrenia!! The company will have free hand in primary kidney cancer for a few years till 2021(combo trials finish that include Cabo!). May land a new indication for liver cancer within next year and is prime acquisition target!! Stop trading. Hang on to your shares, add if you can. Stop paying too much attention to "schizophrenic articles". Cheers to all longs!!
  • B
    Biotech
    Biotech
    So the CEO and CFO sell shares and then the stock get downgraded....I smell a fish, how convenient, shareholder lawsuit coming.
  • J
    John Dsouza
    John Dsouza
    Weak hands continue tfo shake out on a day with positive news. Guess who's buying them up.......that'r right Big Boys, and they will then upgrade and bring us closer to new 52 week high prior to earnings. The CEO at Cantor F. conference today an share price should get back to 27-28 range slowly but surely this week!
  • G
    Gary
    Gary
    Good MF article out today regarding "buy the dip" which is what I have done and what I have been doing since the $2's the next high has always been greater than the previous high with this company. Good things coming, especially with Roche collaboration.
  • R
    Richard
    Richard
    Wow great conference call. Nice slides. Any questions?
  • p
    paul
    paul
    What effect would the Japanese P3 trial on stock price. Any answer and why?
  • H
    Harry
    Harry
    THIS IS GOING TO BE HUGE.
    The positive TL readout from Daichi Sankyo seems to have gone relatively unacknowledged. Japan has 43M hypertensive population of which more than 60% do not respond adequately to the existing medication. This is a huge unmet opportunity. The regulatory approval is expected sometime in 2018 and thereafter it's cha-ching, cha-ching. EXEL is due a double digit royalty on sales and all expenses by DM. Think about it.
  • G
    Gator
    Gator
    Just so much negative news right now and the stock is overvalued. It will probably test $20 short term.
  • N
    Noggin Dog
    Noggin Dog
    Big positive news from Daiichi
  • M
    Marlon
    Marlon
    I saw exel had this types of drop several time in the last year but eventually recovered fairly quick. I think the drop has 3 contributors: too many stop-loss uses, day traders or short term traders scared out. This shaking out makes excellent buying opportunity as the fundamental is still solid. it shouldn't be impacted by just one analyst's $$%% rating, plus this is a out perform to perform. Good thing is a lot people monitoring this stock now have much lower entry point. good for new share holders. There will be a strong bounding back in next Monday.
  • b
    ben
    ben
    Bought on weakness this past Friday!! We should be closing in on 50 bucks soon.
  • i
    itssofine2
    itssofine2
    I see...Shorting by day & covering after hours.
  • R
    Ram
    Ram
    Every stock option the CEO received he sold - doesn't necessarily mean it is a bad thing. He has been doing it continually every option he receives. He receives 1.65 million a year, so he probably is investing it some place else or helping his family out. I am also a long term holder and think that a company that does not have any debt, will eventually be bought out.
  • J
    John Dsouza
    John Dsouza
    Wow this will be a great oppty for new investors to get in and for longs to add.
  • S
    Steve
    Steve

    http://www.businesswire.com/news/home/20170924005050/en/Exelixis-Update-Collaborator-Daiichi-Sankyo%E2%80%99s-Phase-3/

    Exelixis Provides Update on Collaborator Daiichi Sankyo’s Phase 3 Clinical Progress with Esaxerenone (CS-3150), Including Positive Top-Line Results and Additional Pivotal Study
    Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has reported positive to
    www.businesswire.com
  • A
    Alex
    Alex
    adding 40% here at 24.2, remember, no debt in this company. Great opportunity, great growth prospects, patience....